Interleukin-1 deficiency in combination with macrophage depletion increases susceptibility to Pseudomonas aeruginosa bacteremia

Microbiology and Immunology

Volumn 53, Issue 9, 2009, Pages 502-511

  Horino, Tetsuya ^a   Matsumoto, Tetsuya ^b   Ishikawa, Hiroki ^b   Kimura, Soichiro ^c   Uramatsu, Masashi ^c   Tanabe, Masaaki ^c   Tateda, Kazuhiro ^c   Miyazaki, Shuichi ^c   Aramaki, Yukihiko ^d   Iwakura, Yoichiro ^e   Yoshida, Masaki ^a   Onodera, Shoichi ^a   Yamaguchi, Keizo ^c  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Interleukin 1; Macrophage depletion; Neutropenia; Pseudomonas aeruginosa

Indexed keywords

ANTIBODY; CLODRONIC ACID; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL COUNT; BACTERIAL STRAIN; CONTROLLED STUDY; DEPLETION; HOST SUSCEPTIBILITY; IMMUNE DEFICIENCY; INFECTION; INOCULATION; LIVER; MACROPHAGE; MACROPHAGE FUNCTION; MORTALITY; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; ORGAN; PSEUDOMONAS AERUGINOSA; SEPSIS; SURVIVAL; WILD TYPE;

ANIMALS; BACTEREMIA; IMMUNOSUPPRESSION; INTERLEUKIN-1; MACROPHAGES; MICE; MICE, KNOCKOUT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

BACTERIA (MICROORGANISMS); MUS; PSEUDOMONAS AERUGINOSA;

EID: 75749152054     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2009.00143.x     Document Type: Article

References (40)

1. Horino T., Matsumoto T., Uramatsu M., Tanabe M., Tateda K., Miyazaki S., Nakane A., Iwakura Y., Yamaguchi K. (2005) Interleukin-1-deficient mice exhibit high sensitivity to gut-derived sepsis caused by Pseudomonas aeruginosa. Cytokine 30: 339-46.
2. Tadros T., Traber D.L., Heggers J.P., Herndon D.N. (2003) Effects of interleukin-1alpha administration on intestinal ischemia and reperfusion injury, mucosal permeability, and bacterial translocation in burn and sepsis. Ann Surg 237: 101-9.
3. Rijneveld A.W., Florquin S., Branger J., Speelman P., Van Deventer S.J., Van Der Poll T. (2001) TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 167: 5240-6.
4. Tanabe M., Matsumoto T., Shibuya K., Tateda K., Miyazaki S., Nakane A., Iwakura Y., Yamaguchi K. (2005) Compensatory response of IL-1 gene knockout mice after pulmonary infection with Klebsiella pneumoniae. J Med Microbiol 54: 7-13.
5. Bisbe J., Gatell J.M., Puig J., Mallolas J., Martinez J.A., Jimenez de Anta M.T., Soriano E. (1988) Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 10: 629-35.
6. Kang C.I., Kim S.H., Kim H.B., Park S.W., Choe Y.J., Oh M.D., Kim E.C., Choe K.W. (2003) Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 37: 745-51.
7. Vidal F., Mensa J., Almela M., Martinez J.A., Marco F., Casals C., Gatell J.M., Soriano E., Jimenez de Anta M.T. (1996) Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 156: 2121-6.
8. Micek S.T., Lloyd A.E., Ritchie D.J., Reichley R.M., Fraser V.J., Kollef M.H. (2005) Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49: 1306-11.
9. Osmon S.,Ward S., Fraser V.J., Kollef M.H. (2004) Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 125: 607-16.
10. Horai R., Asano M., Sudo K., Kanuka H., Suzuki M., Nishihara M., Takahashi M., Iwakura Y. (1998) Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 187: 1463-75.
11. Hirakata Y., Kaku M., Tomono K., Tateda K., Furuya N., Matsumoto T., Araki R., Yamaguchi K. (1992) Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice. Antimicrob Agents Chemother 36: 1198-1203.
12. Tsai W.C., Strieter R.M., Mehrad B., Newstead M.W., Zeng X., Standiford T.J. (2000) CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect Immun 68: 4289-96.
13. Van Rooijen N. Sanders A. (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.
14. Naito M., Nagai H., Kawano S., Umezu H., Zhu H., Moriyama H., Yamamoto T., Takatsuka H., Takei Y. (1996). Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro. J Leukoc Biol 60: 337-44.
15. Delemarre F.G., Kors N., Kraal G., van Rooijen N. (1990) Repopulation of macrophages in popliteal lymph nodes of mice after liposome-mediated depletion. J Leukoc Biol 47: 251-7.
16. Van Rooijen N., Kors N., vd Ende M., Dijkstra C.D. (1990) Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate. Cell Tissue Res 260: 215-22.
17. Calame W., Mattie H. (1989) Effect of etoposide and cyclophosphamide on an experimental pulmonary infection in mice. Agents Actions 26: 77-8.
18. Matsumoto M., Tamura M., Matsubara S., Matsuno T., Ono M., Yokota T. (1991) Mechanism of protective effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on Pseudomonas infection. Microbiol Immunol 35: 461-74.
19. Mikami Y., Takeda K., Shibuya K., Qiu-Feng H., Shimamura H., Yamauchi J., Egawa S., Sunamura M., Yagi H., Endo Y., Matsuno S. (2003) Do peritoneal macrophages play an essential role in the progression of acute pancreatitis in rats? Pancreas 27: 253-60.
20. Tateda K., Moore T.A., Deng J.C., Newstead M.W., Zeng X., Matsukawa A., Swanson M.S., Yamaguchi K., Standiford T.J. (2001) Early recruitment of neutrophils determines subsequent T1/T2 host responses in a murine model of Legionella pneumophila pneumonia. J Immunol 166: 3355-61.
21. Conlan J.W. (1996) Neutrophils prevent extracellular colonization of the liver microvasculature by Salmonella typhimurium. Infect Immun 64: 1043-7.
22. McIntyre K.W., Unowsky J., DeLorenzo W., Benjamin W. (1989) Enhancement of antibacterial resistance of neutropenic, bone marrow-suppressed mice by interleukin-1 alpha. Infect Immun 57: 48-54.
23. Rogers H.W., Unanue E.R. (1993) Neutrophils are involved in acute, nonspecific resistance to Listeria monocytogenes in mice. Infect Immun 61: 5090-6.
24. Sjostedt A., Conlan J.W., North R.J. (1994) Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect Immun 62: 2779-83.
25. Koh A.Y., Priebe G.P., Pier G.B. (2005) Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun 73: 2262-72.
26. Liu Z.X., Han D., Gunawan B., Kaplowitz N. (2006) Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology 43: 1220-30.
27. Conlan J.W., North R.J. (1994) Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody. J Exp Med 179: 259-68.
28. Broug-Holub E., Toews G.B., van Iwaarden J.F., Strieter R.M., Kunkel S.L., Paine R. 3rd, Standiford T.J. (1997) Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 65: 1139-46.
29. McClellan S.A., Huang X., Barrett R.P., van Rooijen N., Hazlett L.D. (2003) Macrophages restrict Pseudomonas aeruginosa growth, regulate polymorphonuclear neutrophil influx, and balance pro-and anti-inflammatory cytokines in BALB/c mice. J Immunol 170: 5219-27.
30. (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 324: 509-16.
31. Helle M., Brakenhoff J.P., De Groot E.R., Aarden L.A. (1988) Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol 18: 957-9.
32. Hultgren O.H., Svensson L., Tarkowski A. (2002) Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J Immunol 168: 5207-12.
33. Moore T.A., Perry M.L., Getsoian A.G., Newstead M.W., Standiford T.J. (2002) Divergent role of gamma interferon in a murine model of pulmonary versus systemic Klebsiella pneumoniae infection. Infect Immun 70: 6310-8.
34. Van Der Poll T., van Deventer S.J. (1999) Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 13: 413-26, ix.
35. Bjerre A., Brusletto B., Hoiby E.A., Kierulf P., Brandtzaeg P. (2004) Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock. Crit Care Med 32: 433-8.
36. Calandra T., Baumgartner J.D., Grau G.E., Wu M.M., Lambert P.H., Schellekens J., Verhoef J., Glauser M.P. (1990) Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis 161: 982-7.
37. Casey L.C., Balk R.A., Bone R.C. (1993) Plasma cytokine and endotoxin concentrations correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119: 771-8.
38. Damas P., Ledoux D., Nys M., Vrindts Y., De Groote D., Franchimont P., Lamy M. (1992) Cytokine serum concentration during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215: 356-62.
39. Gogos C.A., Drosou E., Bassaris H.P., Skoutelis A. (2000) Proversus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181: 176-80.
40. Dinarello C.A. (1988) Biology of interleukin 1. Faseb J 2: 108-15.